-
04.30.2024 | CARB-X 2023 Annual Report Released Today
The report highlights key takeaways from the strategic review of the portfolio, funding round results, CARB-X’s work in low- and middle-income countries (LMICs), and new CARB-X donors including the Government of Canada and the Novo Nordisk Foundation.
-
04.18.2024 | CARB-X funds Scout to develop a low-cost point-of-care diagnostic for gonorrhea
CARB-X is awarding Scout up to US$1M to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test.
-
03.06.2024 | CARB-X launches new funding round to fill major R&D gaps in global pipeline
CARB-X seeks preventatives of invasive disease, diagnostics for neonatal sepsis and novel sample types for lower respiratory tract infections, and therapeutics for infections caused by gram-negative pathogens.
-
03.05.2024 | CARB-X funds 100th project targeting antibiotic resistance
CARB-X awards US$1.06 million to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), our 100th project to address antibiotic resistance.
-
02.29.2024 | CARB-X funds GlyProVac to develop a novel vaccine to prevent sepsis in newborns
CARB-X is awarding GlyProVac US$467k to develop a maternal vaccine that targets Escherichia coli, a bacterial species that causes a large portion of neonatal sepsis infections.
-
02.27.2024 | CARB-X funds LimmaTech Biologics AG to develop a vaccine that prevents gonorrhea infections
CARB-X is awarding US$2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections.
-
02.13.2024 | CARB-X funds the Myers Research Group to develop enhanced oral antibiotics to treat a range of serious drug-resistant bacterial infections
CARB-X is awarding US$1.2 million to the Andrew G Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology to develop a series of enhanced oral antibiotics that directly target a range of antibiotic-resistant bacteria which cause serious lower respiratory tract and skin and soft tissue infections.
-
02.08.2024 | CARB-X funds Visby Medical to develop a portable rapid diagnostic for gonorrhea including antibiotic susceptibility
CARB-X will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.
-
01.18.2024 | CARB-X is funding Syntiron to develop a maternal vaccine to prevent neonatal sepsis
CARB-X is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.
-
01.16.2024 | CARB-X is funding Intravacc to develop a vaccine that prevents gonorrhea infections
CARB-X is awarding US$633k to Intravacc to develop a vaccine that prevents Neisseria gonorrhoeae bacterial infections.
-
01.09.2024 | Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this space.
Toggle navigation